210 related articles for article (PubMed ID: 34263927)
21. Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients.
Wang Y; Li H; Song X; Qi K; Cheng H; Cao J; Shi M; Yan Z; Jing G; Pan B; Sang W; Wang X; Zhao K; Chen C; Chen W; Zheng J; Li Z; Xu K
Int J Lab Hematol; 2021 Apr; 43(2):250-258. PubMed ID: 33112046
[TBL] [Abstract][Full Text] [Related]
22. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.
Danylesko I; Chowers G; Shouval R; Besser MJ; Jacoby E; Shimoni A; Nagler A; Avigdor A
Curr Res Transl Med; 2020 Jan; 68(1):17-22. PubMed ID: 31882377
[TBL] [Abstract][Full Text] [Related]
23. Infectious Complications in Pediatric, Adolescent and Young Adult Patients Undergoing CD19-CAR T Cell Therapy.
Maron GM; Hijano DR; Epperly R; Su Y; Tang L; Hayden RT; Naik S; Karol SE; Gottschalk S; Triplett BM; Talleur AC
Front Oncol; 2022; 12():845540. PubMed ID: 35356197
[TBL] [Abstract][Full Text] [Related]
24. Late haemophagocytic lymphohistiocytosis in a patient treated with Axicabtagene ciloleucel.
Cutini I; Puccini B; Fabbri A; Santi R; Gozzini A; Nozzoli C; Boncompagni R; Innocenti C; Saccardi R
Transpl Immunol; 2022 Dec; 75():101719. PubMed ID: 36116729
[TBL] [Abstract][Full Text] [Related]
25. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
26. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
[TBL] [Abstract][Full Text] [Related]
27. Chimeric antigen receptor T cell therapy and nephrotoxicity: From diagnosis to treatment strategies.
Zhou H; Yang M; Cui L; Jiang J
Int Immunopharmacol; 2020 Dec; 89(Pt B):107072. PubMed ID: 33059198
[TBL] [Abstract][Full Text] [Related]
28. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
Liu S; Deng B; Yin Z; Lin Y; An L; Liu D; Pan J; Yu X; Chen B; Wu T; Chang AH; Tong C
Am J Hematol; 2021 Jun; 96(6):671-679. PubMed ID: 33725422
[TBL] [Abstract][Full Text] [Related]
29. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
[TBL] [Abstract][Full Text] [Related]
30. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
[TBL] [Abstract][Full Text] [Related]
32. The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma.
Cao JX; Wang H; Gao WJ; You J; Wu LH; Wang ZX
Cytotherapy; 2020 Apr; 22(4):214-226. PubMed ID: 32305113
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
34. Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia.
Jacoby E; Bielorai B; Avigdor A; Itzhaki O; Hutt D; Nussboim V; Meir A; Kubi A; Levy M; Zikich D; Zeltzer LA; Brezinger K; Schachter J; Nagler A; Besser MJ; Toren A
Am J Hematol; 2018 Dec; 93(12):1485-1492. PubMed ID: 30187944
[TBL] [Abstract][Full Text] [Related]
35. Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia.
Zhang X; Li JJ; Lu PH
Chin Med J (Engl); 2020 Feb; 133(4):474-482. PubMed ID: 31977556
[TBL] [Abstract][Full Text] [Related]
36. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.
Dai H; Wu Z; Jia H; Tong C; Guo Y; Ti D; Han X; Liu Y; Zhang W; Wang C; Zhang Y; Chen M; Yang Q; Wang Y; Han W
J Hematol Oncol; 2020 Apr; 13(1):30. PubMed ID: 32245502
[TBL] [Abstract][Full Text] [Related]
37. Interferon-γ blockade in CAR T-cell therapy-associated macrophage activation syndrome/hemophagocytic lymphohistiocytosis.
Rainone M; Ngo D; Baird JH; Budde LE; Htut M; Aldoss I; Pullarkat V
Blood Adv; 2023 Feb; 7(4):533-536. PubMed ID: 35917457
[No Abstract] [Full Text] [Related]
38. Toxicities of CD19 CAR-T cell immunotherapy.
Hirayama AV; Turtle CJ
Am J Hematol; 2019 May; 94(S1):S42-S49. PubMed ID: 30784102
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
40. CAR-T cell therapy in paediatric acute lymphoblastic leukaemia - past, present and future.
Rogosic S; Ghorashian S
Br J Haematol; 2020 Nov; 191(4):617-626. PubMed ID: 33190266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
